T-ALL
MCID: PRC049
MIFTS: 45

Precursor T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards integrated aliases for Precursor T-Cell Acute Lymphoblastic Leukemia:

Name: Precursor T-Cell Acute Lymphoblastic Leukemia 58
T-All 58 54
Precursor T-Cell Acute Lymphoblastic Leukemia/lymphoma 58
Precursor T-Cell Acute Lymphocytic Leukemia/lymphoma 58
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 70
Precursor T-Cell Acute Lymphocytic Leukemia 58
Adult T-Cell Lymphoma/leukemia 70

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C91.0
UMLS via Orphanet 71 C1961099
Orphanet 58 ORPHA99861
UMLS 70 C0023493 C1961099

Summaries for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards based summary : Precursor T-Cell Acute Lymphoblastic Leukemia, also known as t-all, is related to t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Precursor T-Cell Acute Lymphoblastic Leukemia is TLX1 (T Cell Leukemia Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Fludarabine and rituximab have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are cellular and embryo

Related Diseases for Precursor T-Cell Acute Lymphoblastic Leukemia

Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 t-cell acute lymphoblastic leukemia 31.4 TLX3 TLX1 TAL1 STIL NUP214 MYC
2 leukemia, acute lymphoblastic 31.2 TRD TLX3 TLX1 TAL1 PICALM NUP214
3 lymphoblastic lymphoma 31.1 TRB TLX1 TAL1 MYC
4 leukemia 30.9 TLX3 TLX1 TAL1 PICALM MYC MLLT10
5 t-cell lymphoblastic leukemia/lymphoma 30.9 TLX1 TAL1 MYC MYB
6 b-lymphoblastic leukemia/lymphoma 30.9 MYC FLT3 CDKN2A BCR ABL1
7 acute leukemia 30.7 TAL1 MLLT10 FLT3 BCR
8 leukemia, chronic myeloid 30.7 TAL1 MYC MYB FLT3 BCR ABL1
9 leukemia, acute myeloid 30.7 TAL1 PICALM NUP214 MYC MYB MLLT10
10 childhood t-cell acute lymphoblastic leukemia 30.6 TAL1 STIL ABL1
11 myeloid leukemia 30.6 PICALM NUP214 MYC MLLT10 FLT3 BCR
12 childhood leukemia 30.5 CDKN2A BCR ABL1
13 childhood acute lymphocytic leukemia 30.4 TLX1 FLT3 CDKN2A BCR ABL1
14 myelodysplastic syndrome 30.3 NUP214 MYC MYB FLT3 CDKN2A ABL1
15 burkitt lymphoma 30.1 MYC MYB CDKN2A BCR
16 lymphoma, non-hodgkin, familial 29.9 TAL1 MYC MYB FLT3 BCR
17 leukemia, chronic lymphocytic 29.8 MYC MYB FLT3 BCR ABL1
18 philadelphia-negative chronic myeloid leukemia 10.4 BCR ABL1
19 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.4 CDKN2A ABL1
20 cervical adenoid cystic carcinoma 10.4 MYB CDKN2A
21 vulva basal cell carcinoma 10.4 MYC CDKN2A
22 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYC CDKN2A
23 discrete subaortic stenosis 10.4 PICALM MLLT10
24 etv6 thrombocytopenia and predisposition to leukemia 10.4 PICALM NUP214 MLLT10 FLT3
25 cebpa-associated familial acute myeloid leukemia 10.4 PICALM NUP214 MLLT10 FLT3
26 childhood medulloblastoma 10.4 MYC DDX3X CDKN2A
27 suppressor of tumorigenicity 3 10.4 MYC CDKN2A
28 leukemia, acute lymphoblastic 3 10.4 FLT3 CDKN2A BCR ABL1
29 plasmablastic lymphoma 10.4 MYC CDKN2A
30 chronic leukemia 10.4 FLT3 BCR ABL1
31 b-cell adult acute lymphocytic leukemia 10.3 BCR ABL1
32 hematologic cancer 10.3 PICALM MLLT10 FLT3 BCR ABL1
33 b-lymphoblastic leukemia/lymphoma with iamp21 10.3 TLX3 ABL1
34 leukemia, t-cell, chronic 10.3
35 8p11 myeloproliferative syndrome 10.2 FLT3 BCR
36 cowden syndrome 1 10.2
37 retinal detachment 10.2
38 thymoma, familial 10.2
39 sickle cell anemia 10.2
40 lymphoma 10.2
41 rapidly involuting congenital hemangioma 10.2
42 disseminated intravascular coagulation 10.2
43 pancytopenia 10.2
44 myeloproliferative neoplasm 10.2
45 acute pancreatitis 10.2
46 antiphospholipid syndrome 10.2
47 thymoma 10.2
48 pancreatitis 10.2
49 adult acute lymphocytic leukemia 10.2
50 cowden syndrome 10.2

Graphical network of the top 20 diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia:



Diseases related to Precursor T-Cell Acute Lymphoblastic Leukemia

Symptoms & Phenotypes for Precursor T-Cell Acute Lymphoblastic Leukemia

MGI Mouse Phenotypes related to Precursor T-Cell Acute Lymphoblastic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ABL1 BCR CDKN2A CNOT3 DDX3X FLT3
2 embryo MP:0005380 10.18 ABL1 CDKN2A CNOT3 DDX3X MLLT10 MYB
3 hematopoietic system MP:0005397 10.06 ABL1 BCR CDKN2A CNOT3 FLT3 HNRNPH1
4 immune system MP:0005387 10.03 ABL1 BCR CDKN2A CNOT3 FLT3 HNRNPH1
5 mortality/aging MP:0010768 9.86 ABL1 BCR CDKN2A CNOT3 DDX3X FLT3
6 liver/biliary system MP:0005370 9.7 ABL1 BCR CDKN2A CNOT3 MYB MYC
7 nervous system MP:0003631 9.4 ABL1 BCR CDKN2A DDX3X MLLT10 MYB

Drugs & Therapeutics for Precursor T-Cell Acute Lymphoblastic Leukemia

Drugs for Precursor T-Cell Acute Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
2
rituximab Approved Phase 3 174722-31-7 10201696
3
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
4
Azathioprine Approved Phase 3 446-86-6 2265
5
Idarubicin Approved Phase 3 58957-92-9 42890
6
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
7
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
17
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Mercaptopurine Approved Phase 3 50-44-2 667490
20
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
21
Ichthammol Approved Phase 3 8029-68-3
22
Daunorubicin Approved Phase 3 20830-81-3 30323
23
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
24
Thioguanine Approved Phase 3 154-42-7 2723601
25
Ifosfamide Approved Phase 3 3778-73-2 3690
26
leucovorin Approved Phase 3 58-05-9 6006
27
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
28
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
29
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
32
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
33
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
36
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
37
Aclarubicin Investigational Phase 3 57576-44-0 451415
38
Cortisone Experimental Phase 3 53-06-5 222786
39
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
40 Protein Kinase Inhibitors Phase 3
41 Antineoplastic Agents, Immunological Phase 3
42
Homoharringtonine Phase 3 285033
43 Imatinib Mesylate Phase 3 220127-57-1 123596
44 razoxane Phase 3
45 Cardiotonic Agents Phase 3
46 Etoposide phosphate Phase 3
47 Immunosuppressive Agents Phase 3
48 Immunologic Factors Phase 3
49 Antiviral Agents Phase 3
50 Antimetabolites Phase 3

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
2 A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Recruiting NCT04446130 Phase 3 Decitabine combined with HAAG Regimen
3 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
4 Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
5 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
6 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
7 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
8 Phase I/II Study of Ruxolitinib Plus L-asparaginase, Vincristine, and Prednisone in Adult Patients With Relapsed or Refractory Early T Precursor Acute Lymphocytic Leukemia Unknown status NCT03613428 Phase 1, Phase 2 Ruxolitinib;Vincristine;Prednisone
9 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
10 Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7) Completed NCT00684619 Phase 2 Nelarabine
11 A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
12 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
13 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
14 German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
15 Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine Sulfate
16 A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Recruiting NCT04315324 Phase 2 AKR1C3-activated Prodrug OBI-3424
17 Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03808610 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Venetoclax;Vincristine
18 A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
19 A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
20 An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
21 A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell ALL, and Mixed Phenotype Acute Leukemia Recruiting NCT04128501 Phase 2 Azacitidine;Venetoclax
22 A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies Recruiting NCT04033302 Phase 1, Phase 2
23 Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children Recruiting NCT04340154 Phase 2
24 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT02484430 Phase 2 Sapanisertib
25 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
26 Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
27 A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
28 A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Terminated NCT02767934 Phase 2
29 A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
30 A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens. Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
31 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated NCT01483690 Phase 1, Phase 2 Decitabine;Vorinostat;Vincristine;Dexamethasone;Mitoxantrone;Pegaspargase;Methotrexate
32 A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Terminated NCT00742495 Phase 1, Phase 2 Forodesine
33 A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma Withdrawn NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
34 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
35 Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors Completed NCT00640796 Phase 1 Chemotherapy
36 Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT01363817 Phase 1 BMS-906024;Dexamethasone
37 A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma Completed NCT01403415 Phase 1 Dexamethasone;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Temsirolimus;Vincristine Sulfate
38 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
39 A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT03519984 Phase 1 Cytarabine;Vincristine Liposomal
40 A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies Recruiting NCT04681105 Phase 1 Acetaminophen;Dexamethasone;Diphenhydramine;Ibuprofen;Ranitidine
41 Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting NCT03081910 Phase 1 Fludarabine;Cytoxan
42 Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies Recruiting NCT04594135 Phase 1 anti-CD5 CAR T cells
43 The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies Recruiting NCT04828174 Phase 1 anti-TRBC1 CAR-T cell therapy
44 A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias Active, not recruiting NCT01139970 Phase 1 Temozolomide;Veliparib
45 Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Active, not recruiting NCT04185220 Phase 1 rhIL-15
46 Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON) Not yet recruiting NCT03690011 Phase 1 Fludarabine;Cytoxan
47 A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Terminated NCT01186328 Phase 1 EZN-3042;Cytarabine;Doxorubicin;Prednisone;Vincristine;PEG-asparaginase;Methotrexate;Hydrocortisone
48 A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma Terminated NCT00100152 Phase 1 MK0752, (Notch Inhibitor)
49 Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol Unknown status NCT02638922 Estradiol
50 Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome Completed NCT01295476

Search NIH Clinical Center for Precursor T-Cell Acute Lymphoblastic Leukemia

Genetic Tests for Precursor T-Cell Acute Lymphoblastic Leukemia

Anatomical Context for Precursor T-Cell Acute Lymphoblastic Leukemia

MalaCards organs/tissues related to Precursor T-Cell Acute Lymphoblastic Leukemia:

40
Myeloid, T Cells, Bone Marrow, Thymus, Liver, B Cells, Prostate

Publications for Precursor T-Cell Acute Lymphoblastic Leukemia

Articles related to Precursor T-Cell Acute Lymphoblastic Leukemia:

(show top 50) (show all 3958)
# Title Authors PMID Year
1
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. 54 61
20516195 2010
2
Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. 54 61
20155852 2010
3
Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. 61 54
20459861 2010
4
T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. 54 61
19631984 2010
5
Genetic inactivation of Ikaros is a rare event in human T-ALL. 61 54
19796813 2010
6
Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. 54 61
19608273 2010
7
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. 54 61
20124220 2010
8
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. 54 61
20015880 2010
9
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 61 54
19559479 2010
10
Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia. 54 61
20374994 2010
11
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 61 54
20093438 2010
12
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 61 54
20008304 2010
13
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 54 61
20161710 2010
14
Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. 61 54
20208138 2010
15
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 54 61
20023257 2010
16
NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells. 54 61
19835636 2009
17
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 54 61
19564891 2009
18
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. 61 54
19635999 2009
19
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. 54 61
19340001 2009
20
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. 54 61
19357700 2009
21
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. 61 54
19458356 2009
22
WT1 mutations in T-ALL. 54 61
19494353 2009
23
CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. 61 54
19469710 2009
24
The mechanism of chemokine receptor 9 internalization triggered by interleukin 2 and interleukin 4. 54 61
19567201 2009
25
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. 61 54
19246562 2009
26
Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. 61 54
19171877 2009
27
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. 54 61
19091404 2009
28
[Functional analysis of notch in the pathophysiology of leukemia]. 61 54
19489437 2009
29
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. 61 54
19245433 2009
30
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. 61 54
19109228 2009
31
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. 61 54
19351820 2009
32
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. 61 54
19318552 2009
33
The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. 54 61
19055661 2009
34
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. 54 61
19185842 2009
35
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. 61 54
19001083 2009
36
The role of NOTCH1 signaling in T-ALL. 54 61
20008221 2009
37
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. 54 61
19778842 2009
38
Notch1 is a frequent mutational target in chemically induced lymphoma in mouse. 54 61
18798262 2008
39
CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. 61 54
18683236 2008
40
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. 54 61
18830414 2008
41
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. 61 54
18981238 2008
42
Relative expression of different Ikaros isoforms in childhood acute leukemia. 61 54
18675565 2008
43
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. 61 54
18835836 2008
44
[Comparative analysis of blast immunophenotype between the diagnosis and relapse of childhood acute lymphoblastic leukaemia - implications for monitoring of minimal residual disease]. 61 54
19531824 2008
45
[Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols]. 61 54
19176062 2008
46
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. 61 54
18677410 2008
47
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. 54 61
18765521 2008
48
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. 54 61
18577685 2008
49
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. 54 61
18411416 2008
50
Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution. 61 54
18617057 2008

Variations for Precursor T-Cell Acute Lymphoblastic Leukemia

Expression for Precursor T-Cell Acute Lymphoblastic Leukemia

Search GEO for disease gene expression data for Precursor T-Cell Acute Lymphoblastic Leukemia.

Pathways for Precursor T-Cell Acute Lymphoblastic Leukemia

Pathways related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 MYC FLT3 CDKN2A BCR ABL1
2 12.38 MYC FLT3 CDKN2A BCR ABL1
3 11.74 TLX3 TLX1 MYC FLT3
4 11.6 MYC CDKN2A ABL1
5
Show member pathways
10.47 MYC CDKN2A ABL1
6 10.14 MYC CDKN2A ABL1

GO Terms for Precursor T-Cell Acute Lymphoblastic Leukemia

Cellular components related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.03 STIL PICALM NUP214 MYB MLLT10 HNRNPH1
2 nucleus GO:0005634 9.83 TLX3 TLX1 TAL1 SALL2 PICALM NUP214
3 protein-containing complex GO:0032991 9.17 TAL1 MYC MLLT10 FLT3 CDKN2A BCR
4 alpha-beta T cell receptor complex GO:0042105 9.16 TRB TRA

Biological processes related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of hematopoietic stem cell differentiation GO:1902036 9.54 TAL1 MYB ABL1
2 hemopoiesis GO:0030097 9.5 TAL1 PICALM FLT3
3 regulation of stem cell population maintenance GO:2000036 9.43 TAL1 CNOT3
4 positive regulation of neuron death GO:1901216 9.43 PICALM MYB ABL1
5 negative regulation of ubiquitin-protein transferase activity GO:0051444 9.4 CDKN2A ABL1
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 TLX1 TAL1 SALL2 MYC MYB MLLT10
7 T cell mediated cytotoxicity directed against tumor cell target GO:0002419 9.16 TRB TRA
8 detection of tumor cell GO:0002355 8.96 TRB TRA

Molecular functions related to Precursor T-Cell Acute Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.32 TLX3 TLX1 TAL1 SALL2 MYC MYB

Sources for Precursor T-Cell Acute Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....